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ABBREVIATIONS 
 
ABL1   c-abl oncogene 1, receptor tyrosine kinase 
aCGH, array-CGH array comparative genomic hybridization 
ADAMTS8  ADAM metallopeptidase with thrombospondin type 1 motif, 8 
AML   acute myeloid leukemia 
APLP2   amyloid beta (A4) precursor-like protein 2 
ARHGEF12 (LARG) Rho guanine nucleotide exchange factor (GEF) 12 
ATM   ataxia telangiectasia mutated 
BAALC   brain and acute leukemia, cytoplasmic 
BAC   bacterial artificial chromosome 
BARX2   BARX homeobox 2 
BCR   breakpoint cluster region 
bp   base pair 
CBFB   core-binding factor, beta subunit 
CBL   Cas-Br-M (murine) ecotropic retroviral transforming sequence 
CCDC26  coiled-coil domain containing 26 
cCGH   chromosomal comparative genomic hybridization 
cDNA   complementary deoxyribonucleic acid 
CEBPA   CCAAT/enhancer binding protein (C/EBP), alpha 
CLL   chronic lymphocytic leukemia 
CNV   copy number variation 
CREBBP  CREB binding protein 
CUL5   cullin 5 
DEK   DEK oncogene 
dmin   double minute chromosome 
ERG   v-ets erythroblastosis virus E26 oncogene homolog (avian) 
ETS1   v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)  
ETV6   ets variant 6 
EVI1   ecotropic viral integration site 1 
FAB    French-American-British  
FAM84B  family with sequence similarity 84, member B 
FISH   fluorescence in situ hybridization 
FLI1   Friend leukemia virus integration 1 
FLT3   fms-related tyrosine kinase 3 
hsr   homogeneously staining region 
IgVH   immunologlobulin variable heavy chain 
ITD   internal tandem duplication 
JAM3   junctional adhesion molecule 3 
KCNJ1   potassium inwardly-rectifying channel, subfamily J, member 1 
KCNJ5   potassium inwardly-rectifying channel, subfamily J, member 5 
KIT   v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
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KRAS   v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LOH   loss of heterozygosity 
MDS   myelodysplastic syndrome 
M-FISH   multiplex fluorescence in situ hybridization 
MIR15A   microRNA 15a 
MIR16-1 microRNA 16-1 
MIR181 microRNA 181 
MIR29 microRNA 29 
MLL myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 
MLPA multiplex ligation-dependent probe amplification 
MN1   meningioma (disrupted in balanced translocation) 1 
MRD   minimal residual disease 
MYC   v-myc myelocytomatosis viral oncogene homolog (avian) 
MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived 
(avian) 
MYH11   myosin, heavy chain 11, smooth muscle 
MYST3   MYST histone acetyltransferase (monocytic leukemia) 3 
NCAPD3  non-SMC condensin II complex, subunit D3 
NFRKB   nuclear factor related to kappaB binding protein 
NGS   next-generation sequencing 
NPAT   nuclear protein, ataxia-telangiectasia locus 
NPM1   nucleophosmin (nucleolar phosphoprotein B23, numatrin) 
NRAS   neuroblastoma RAS viral (v-ras) oncogene homolog 
NTM   neurotrimin 
NUP214  nucleoporin 214kDa 
OPCML   opioid binding protein/cell adhesion molecule-like 
p   short chromosome arm 
PML   promyelocytic leukemia 
PPP2R1B  protein phosphatase 2 (formerly 2A), regulatory subunit A, beta isoform 
PVT1   Pvt1 oncogene (non-protein coding) 
q   long chromosome arm 
qRT-PCR  quantitative real-time polymerase chain reaction 
RARA   retinoic acid receptor, alpha 
RFLP    restriction fragment length polymorphism  
RICS   Rho GTPase-activating protein 
RUNX1   runt-related transcription factor 1 
RUNX1T1  runt-related transcription factor 1; translocated to, 1 (cyclin D-related) 
SKY   spectral karyotyping 
SNP   single-nucleotide polymorphism 
SNP-array  single-nucleotide polymorphism microarray 
SNX19   sorting nexin 19 
SRPR   signal recognition particle receptor (docking protein) 
ST14   suppression of tumorigenicity 14 (colon carcinoma) 
TCL1   T-cell leukemia/lymphoma 1 
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TP53   tumor protein p53 
TRIB1   tribbles homolog 1 (Drosophila) 
UPD   uniparental disomy 
WGG   whole genome genotyping  
WGSA   whole genome sampling assay  
WHO   World Health Organization  
WT1   Wilms tumor 1 
ZAP70   zeta-chain (TCR) associated protein kinase 70kDa 
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ABSTRACT 
 
Chromosomal alterations in leukemia have been shown to have prognostic and 
predictive significance and are also important minimal residual disease (MRD) markers 
in the follow-up of leukemia patients. Although specific oncogenes and tumor 
suppressors have been discovered in some of the chromosomal alterations, the role and 
target genes of many alterations in leukemia remain unknown. In addition, a number of 
leukemia patients have a normal karyotype by standard cytogenetics, but have 
variability in clinical course and are often molecularly heterogeneous. Cytogenetic 
methods traditionally used in leukemia analysis and diagnostics; G-banding, various 
fluorescence in situ hybridization (FISH) techniques, and chromosomal comparative 
genomic hybridization (cCGH), have enormously increased knowledge about the 
leukemia genome, but have limitations in resolution or in genomic coverage. In the last 
decade, the development of microarray comparative genomic hybridization (array-
CGH, aCGH) for DNA copy number analysis and the SNP microarray (SNP-array) 
method for simultaneous copy number and loss of heterozygosity (LOH) analysis has 
enabled investigation of chromosomal and gene alterations genome-wide with high 
resolution and high throughput. 
In these studies, genetic alterations were analyzed in acute myeloid leukemia 
(AML) and chronic lymphocytic leukemia (CLL). The aim was to screen and 
characterize genomic alterations that could play role in leukemia pathogenesis by using 
aCGH and SNP-arrays. One of the most important goals was to screen cryptic 
alterations in karyotypically normal leukemia patients. In addition, chromosomal 
changes were evaluated to narrow the target regions, to find new markers, and to obtain 
tumor suppressor and oncogene candidates. 
The work presented here shows the capability of aCGH to detect submicroscopic 
copy number alterations in leukemia, with information about breakpoints and genes 
involved in the alterations, and that genome-wide microarray analyses with aCGH and 
SNP-array are advantageous methods in the research and diagnosis of leukemia. The 
most important findings were the cryptic changes detected with aCGH in karyotypically 
normal AML and CLL, characterization of amplified genes in 11q marker 
chromosomes, detection of deletion-based mechanisms of MLL-ARHGEF12 fusion 
gene formation, and detection of LOH without copy number alteration in karyotypically 
normal AML. These alterations harbor candidate oncogenes and tumor suppressors for 
further studies.
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INTRODUCTION 
 
The cancer genome is affected by various genetic alterations, including mutations, 
epigenetic alterations, and such chromosomal alterations as translocations, copy number 
changes, and loss of heterozygosity (LOH). These alterations can cause inactivation of 
tumor suppressor genes or activation of oncogenes. Eventually, the expression of genes 
and proteins is changed, forming the cancer phenotype. 
Leukemia is a hematological cancer characterized by malignant clonal growth of 
blood cells. Cytogenetic and genetic alterations are important prognostic and predictive 
factors that affect the diagnosis and treatment of leukemia patients (Swerdlow et al. 
2008). More detailed analysis of the chromosomal alterations detected in leukemia is 
important for obtaining knowledge of the pathogenesis of leukemia. In addition, the 
knowledge about the genes that are targets of chromosomal changes can provide target 
genes for therapies. More precise classification of the patients to different risk groups 
can improve the targeting of available treatments to those patients who will benefit from 
them. 
Modern microarray techniques provide possibilities for detailed analysis of the 
DNA alterations in the cancer genome. Genome-wide analysis with array comparative 
genomic hybridization (array-CGH, aCGH) and single-nucleotide polymorphism 
microarrays (SNP-array) can reveal small cryptic copy number changes that are relevant 
in leukemogenesis. Moreover, the novel alterations detected with these microarray 
methods may serve as putative minimal residual disease markers. Besides the copy 
number alterations found with both methods, SNP-array can also reveal copy number 
neutral allelic loss. SNP-array and aCGH may prove to be useful in leukemia 
diagnostics as molecular karyotyping techniques that provide additional information to 
such traditional cytogenetic analyses as G-banding and fluorescence in situ 
hybridization (FISH). 
This thesis concentrates on the genetic analyses of two different leukemias, 
acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). The main 
focus is on the analysis of chromosomal alterations in leukemic cells using high-
resolution genome-wide analyses with aCGH and SNP-array. 
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REVIEW OF THE LITERATURE 
 
1. Cancer and genetic alterations 
 
Cancer is a common disease worldwide, often associated with aging. It is detected in 
various tissues and has a complex genetic background. Most of the genetic alterations in 
cancer are acquired somatically, although in some cases inherited mutations may also 
lead to susceptibility. In families with inherited susceptibility, cancer can be detected in 
many close relatives and specific cancer types can be common. In addition, in these 
families cancer is often detected in young individuals. Specific mutations can be 
detected in inherited forms of cancer in the same cancer genes that are often altered in 
somatic cancer. Some inherited cancers also have inherited defects in repair genes, 
leading to genetic instability and accumulation of mutations. In many cases, the cause of 
the cancer is unknown, but such factors as mistakes during DNA replication or exposure 
to various environmental factors, including carcinogenic chemicals, viruses, and 
radiation, have been suggested. The main hallmarks of cancer are (1) self-sufficient 
growth, (2) insensitivity to antigrowth signals, (3) limitless replicative potential, (4) 
evasion of apoptosis, (5) angiogenesis, and (6) tissue invasion and metastasis (Hanahan 
& Weinberg 2000). These processes are strictly controlled at various levels in the 
normal genome. Accumulation of aberrations in these processes and malfunction of 
normal repair mechanisms can lead to aberrant growth of cells and cancer development. 
Clonal proliferation starting from a single progenitor cell is a typical 
characteristic of cancer. Cancer development is thought to occur in multiple steps, with 
a minimum of 3-6 mutations (Vogelstein & Kinzler 1993). Multiple mutations in 
progenitor cells start uncontrolled proliferation, and accumulating alterations induce 
malignant transformation. Alterations accumulate in the genes involved in cell 
proliferation, cell differentiation, cell death, and DNA repair (Futreal et al. 2004). The 
sequence of cancer genes can be altered by point mutations or base pair (bp) level 
deletions, insertions, and inversions or by chromosomal alterations, including changes 
in ploidy and individual chromosome numbers, chromosomal deletions, amplifications, 
and translocations (reviewed by Lengauer et al. 1998). Epigenetic alterations that do not 
affect the DNA sequence can silence genomic regions involved in cancer pathogenesis 
by covalent modifications of chromatin components or DNA methylation (reviewed by 
Jones & Baylin 2002). Of the approximately 25 000 genes in the human genome, over 
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1% have been reported to be involved in cancer (Futreal et al. 2004). Cancer genes are 
generally categorized to two types, oncogenes and tumor suppressors. 
Proto-oncogenes are the normally functioning genes coding growth factors, 
growth factor receptors, signaling proteins, and transcription factors. These genes can 
become oncogenes by gaining an abnormal function. Oncogenes typically have a 
dominant activity; only one of the alleles needs to be affected. Activation or 
deregulation of oncogenes can be caused by mechanisms of amplification, mutation, or 
chromosomal rearrangements such as translocation, inversion, and interstitial deletion. 
Genes that normally function in preventing cancer-causing aberrations in the 
genome and cells are called tumor suppressors. In cancer cells, tumor suppressors can 
be inactivated by deletion of one or both of the alleles, mutations in the gene sequence, 
or epigenetic silencing. According to Knudson's (1971) two-hit hypothesis, a minimum 
of two alterations are needed to inactivate the tumor suppressor. Currently we know that 
although alterations in both tumor suppressor alleles are usually needed, in cases of 
haploinsufficiency, dominant-negative mutations, or imprinting, one change can be 
sufficient (reviewed by Payne & Kemp 2005). Tumor suppressors are divided into three 
classes: genes that protect the genome from oncogenic mutations and include repair and 
segregator genes (caretakers), genes that prevent malignant growth by inducing 
apoptosis or inhibiting growth (gatekeepers), and landscaper genes that affect the 
microenvironment of cells (Kinzler & Vogelstein 1997, Kinzler & Vogelstein 1998). 
Loss of caretaker gene functions associated with genomic instability is suggested to be 
involved in most cancers and is reflected as an increased rate of alterations in the DNA 
sequence and chromosomes (reviewed by Lengauer et al. 1998, Hoeijmakers 2001). 
 
 
2. Chromosomal imbalances in cancer 
 
In cancer cells, various chromosomal imbalances changing the chromosome number or 
rearranging the structure of chromosomes are common. Chromosomal imbalances in 
cancers have been studied extensively for diagnostic and classification purposes, for 
discovery of treatment targets, and for elucidation of pathogenic mechanisms. 
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2.1. Translocations and inversions 
 
Translocations are structural changes that arise when a chromosomal segment is 
relocated from its normal position in the genome. Various types of translocations are 
seen in cancer. In balanced translocations, no copy number alterations are detectable in 
cytogenetic analyses, whereas in unbalanced translocations gains and losses are seen. 
Simple translocations, which are composed recurrently of the same DNA segments, are 
common in leukemia and lymphoma, while more random, complex translocations, 
associated with various chromosomal imbalances, are more common in solid tumors 
(Lengauer et al. 1998). Inversions are balanced structural changes occurring within one 
chromosome as a result of two DNA breaks, 180° inversion, and subsequent re-joining. 
The exact mechanisms of translocations and fusion gene formation remain unknown, 
but DNA double-strand breaks and subsequent incorrect repair mechanisms have been 
suggested to be involved (reviewed by Elliott & Jasin 2002, Aplan 2006). 
 Translocations and inversions can form oncogenic fusion genes or bring an 
oncogene into the vicinity of a strong regulator sequence that causes aberrant activation. 
Oncogenic fusion genes are often transcription factors or tyrosine kinases (Look 1997, 
Mitelman et al. 2004). The most commonly known example of an oncogenic fusion 
gene caused by a translocation is the BCR-ABL1 tyrosine kinase detected in the 
Philadelphia chromosome in chronic myeloid leukemia (reviewed by Laurent et al. 
2001). Currently, over 440 different fusion genes have been detected in cancer 
(Mitelman et al. 2007, Heim & Mitelman 2008). Based on detection of specific fusion 
genes, some leukemias and lymphomas can be classified into subtypes (Swerdlow et al. 
2008). Although fusion genes can have an important role in developing a specific 
cancer, fusion genes have also been detected in healthy individuals (Janz et al. 2003), 
and the formation of cancer is thought to require additional alterations. For example, in 
AML, a specific fusion gene and an oncogenic mutation are frequently simultaneously 
present (Dash & Gilliland 2001). 
 
 
2.2. DNA copy number losses 
 
DNA copy number loss is one of the mechanisms of tumor suppressor inactivation. In 
Knudson's two-hit hypothesis, one of the tumor suppressor alleles is mutated and the 
second allele is then lost (Knudson 1971). DNA copy number losses are common in 
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solid tumors and also recurrent in hematological malignancies. Losses have been found 
in all chromosome arms in cancer (Knuutila et al. 1999), and they are detected as 
monosomies, deletions of chromosomal segments, and loss of DNA associated with 
unbalanced translocations. Defining minimal common regions of loss in particular 
cancers is a popular strategy in searching for tumor suppressors.  
Whole chromosome losses in cancer cells can be caused by mitotic errors, 
whereas DNA breaks are involved in the formation of structural deletions. One break 
can cause terminal loss of material from the chromosome, and two breaks can cause 
interstitial deletion when the DNA between the breaks is lost and the resulting DNA 
ends are fused. Besides causing the loss of tumor suppression, in some cases interstitial 
deletion can also form a fusion gene, thus being a mechanism of oncogene activation 
(Kourlas et al. 2000, Van Vlierberghe et al. 2008). 
 
 
2.3. Amplifications 
 
Amplification is considered to be a late or secondary event in cancer and is one of the 
mechanisms that can cause the overexpression of oncogenes (Lengauer et al. 1998). 
Amplicons are formed of multiple copies of a DNA sequence that is generally under 10 
Mb long, whereas copy number gains are generally larger, with fewer copies, and 
detected as aneuploidy or with unbalanced translocations (reviewed by Myllykangas & 
Knuutila 2006). All of the genes in the amplicon may not be overexpressed and are 
called bystanders. An estimated 20-60% of amplified genes show overexpression 
(Hyman et al. 2002, Pollack et al. 2002, Heidenblad et al. 2005). 
Amplifications are detected as homogeneously staining regions (hsrs) within 
chromosomes or as extrachromosomal structures, including double minute 
chromosomes (dmins), episomes, and various larger marker chromosomes, e.g. ring 
chromosomes. Dmins are small circular chromatin structures that are detectable under a 
light microscope, and episomes are circular DNA particles (<1 Mb) not detectable in 
standard karyotyping. Amplicons located in chromosomes are more stable than 
extrachromosomal particles because in cell division they segregate with chromosomes, 
whereas extrachromosomal structures segregate randomly and may be lost in the 
process. However, if the particles include genes that have a selective advantage (e.g. 
oncogenes in cancer tissue), their amount may increase (reviewed by Hahn 1993). 
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Various models have been suggested for explaining the formation of 
amplifications such as the breakage-fusion-bridge model, the episome model, and the 
overreplication model (“onion skin model”) (Schimke et al. 1986, Carroll et al. 1988, 
Von Hoff et al. 1990, reviewed by Myllykangas & Knuutila 2006,). In the 
overreplication model, replication of DNA is disrupted and overreplication occurs. 
These overreplicated DNA strands can then ligate together from the ends and recombine 
to chromosomes or form circular extrachromosomal particles (Schimke et al. 1986). In 
the episome model, a deletion of a chromosomal segment occurs first, after which the 
deleted segment forms the episome (Carroll et al. 1988). Episomes can then form dmins 
by enlarging (Carroll et al. 1988). Episomes and dmins may also integrate to 
chromosomes and form hsrs (Carroll et al. 1988). Breakage-fusion-bridge cycles can 
form hsrs, ring chromosomes, and other unspecific chromosomal changes: first, double-
strand DNA breakage or telomere erosion occurs and, after replication, the uncapped 
ends of sister chromatides fuse, then in mitosis an anaphase bridge is formed and a 
second asymmetric breakage may occur in the bridge, resulting in one daughter cell 
with a duplicated oncogene and one with a deletion of that gene (Schwab 1999, 
Gisselsson et al. 2000, Myllykangas & Knuutila 2006). 
 
 
2.4. Loss of heterozygosity 
 
In loss of heterozygosity (LOH), one of the two heterozygous alleles is lost. As a result 
of LOH, the heterozygous chromosomal region becomes homozygous or hemizygous. 
Homozygous LOH is detected when one allele is lost and the other is duplicated. In 
hemizygous LOH, only one allele remains when the other is deleted. Because LOH 
analysis detects allelic imbalance, it can reveal copy number changes as well as copy 
number neutral LOH. LOH can be detected to varying extents, from localized alteration 
of one allele to whole chromosome alteration. Various mechanisms, including deletion, 
gene conversion, mitotic recombination, translocation, and nondisjunction, have been 
shown or suggested to cause LOH (Thiagalingam et al. 2002). 
In cancer, LOH has been considered a marker for a tumor suppressor gene based 
on Knudson’s two-hit hypothesis. According to his hypothesis, a recessive tumor 
suppressor gene is first mutated and the remaining wild-type allele is then lost with a 
second hit such as LOH (Knudson 1971). Besides mutation, one allele of the recessive 
gene can also be silenced by epigenetic mechanism (Jones & Baylin 2002), and LOH 
then causes loss of function of the gene. An additional mechanism associated with LOH 
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can be haploinsufficiency, when one functional allele is not sufficient to prevent disease 
(Payne & Kemp 2005). Genomic instability in cancer, which can be caused by 
malfunction of caretaker and segregator genes, is associated with frequent LOH 
(Thiagalingam et al. 2002). 
 
 
2.5. Uniparental disomy 
 
In uniparental disomy (UPD), one of the homologous parental chromosomes is lost and 
the other is duplicated (Engel 1980). Engel’s concept of UPD explained the large 
homozygous chromosomal segments in abnormal fetuses and suggested the meiotic 
mechanisms behind constitutional UPD. Since then, the concept of UPD has broadened 
to also include acquired UPD, which is created by mitotic mechanisms. Two types of 
UPD exist. In heterodisomy, both homologous chromosomes of one parent are present, 
while in isodisomy the homologous chromosomes are identical copies from one 
homolog of one parent. Heterodisomy causes abnormalities only when combined with 
loss of imprinting and does not affect heterozygosity. Isodisomy, by contrast, causes 
LOH. 
UPD mechanisms in meiosis include gamete complementation, trisomy 
correction, and monosomy duplication (reviewed by Robinson 2000, Tuna et al. 2009). 
Contrary to meiotic UPD, which can be seen in each progeny cell, mitotic UPD is 
present only in a portion of cells. UPD mechanisms proposed to cause acquired UPD 
include somatic recombination, and mitotic nondisjunction and subsequent duplication 
of the chromosomes (Robinson 2000, Tuna et al. 2009). Gene conversion has also been 
suggested to cause small regions of isodisomy (Robinson 2000), but may be too rare an 
event in humans to be a significant cause (Tuna et al. 2009). Compensatory UPD occurs 
when a chromosomal aberration or a lost chromosome is replaced by copying the 
normal homolog (Robinson 2000). 
Analysis of UPD-causing mechanisms and elucidation of the importance of UPD 
in cancer formation are ongoing challenges. Because of the high rate of cell divisions in 
cancer tissue, UPD can be a common event in cancer. In recent years, acquired UPD has 
frequently been discovered in various cancers, mostly by using modern SNP-array 
technologies (Raghavan et al. 2005, Tuna et al. 2009). The degree of UPD detected in 
cancer includes both whole chromosome UPD, as well as telomeric or interstitial UPDs. 
UPD in the cancer genome can cause inactivation of tumor suppressors or activation of 
oncogenes. Possible pathogenic consequences of UPD include homozygosity of a 
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mutated recessive gene or gene expression changes caused by a combination of UPD 
and epigenetic mechanisms in regulator sequences (Tuna et al. 2009). 
 
 
3. Microarrays in the analysis of chromosomal imbalances 
 
G-banding karyotyping is traditionally used to detect structural and numeric 
chromosomal changes under a light microscope. Molecular cytogenetic methods, such 
as fluorescence in situ hybridization (FISH) (Pinkel et al. 1986, reviewed by Trask 
1991), multiplex FISH (M-FISH) (Speicher et al. 1996), spectral karyotyping (SKY) 
(Schrock et al. 1996), multicolor chromosome banding (Muller et al. 1998, Chudoba et 
al. 1999), and chromosomal comparative genomic hybridization (cCGH) (Kallioniemi 
et al. 1992) have improved the resolution of cytogenetic analysis. In addition, molecular 
genetic analyses, e.g. quantitative real-time PCR (qRT-PCR) (reviewed by Mocellin et 
al. 2003) or multiplex ligation-dependent probe amplification (MLPA) (Schouten et al. 
2002), have been used to study chromosomal changes in detail. 
Knowledge of the structures of genomes and chromosomes, gene mapping, and 
the sequence of the whole human genome has enabled development of DNA 
microarrays, which are composed of an organized set of DNA probes spotted on a chip. 
Modern microarrays can contain hundreds of thousands of probes, allowing a genome-
wide analysis with a high throughput and high resolution and producing a large number 
of data in a single experiment. Various DNA microarray analyses with specific 
platforms have been developed, including gene expression, genotyping, epigenetic, and 
aCGH microarray analyses (reviewed by Hoheisel 2006). 
 
 
3.1. Array comparative genomic hybridization 
 
Development of cCGH has enabled study of genome-wide DNA copy number 
alterations without cell culturing (Kallioniemi et al. 1992). The principle of the cCGH 
method is that DNA from the test material (e.g. tumor DNA) and reference material are 
labeled with different colors and hybridized together to the metaphase slides. The 
relative signal ratio of test and reference is measured with a microscope and image 
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analysis software and turned into a copy number profile, showing gains and losses of 
material. 
Because resolution of cCGH is limited to a chromosome-band level, a new 
technique known as aCGH was developed (Solinas-Toldo et al. 1997, Pinkel et al. 1998, 
Pollack et al. 1999). Array-CGH enables genome-wide analysis of the copy number 
alterations in a single experiment with a resolution that can detect gene-level or even 
exon-level changes. A relatively small amount of DNA is needed in an aCGH 
experiment (200 ng to 1 µg). Furthermore, DNA extracted from paraffin-embedded 
tissue or produced with whole genome amplification can also be used (Cardoso et al. 
2004, Guillaud-Bataille et al. 2004, Lips et al. 2005, Hittelman et al. 2007). 
As in cCGH, in an aCGH experiment the sample DNA is compared with 
reference DNA (Figure 1). The main difference is that instead of metaphase 
chromosomes the hybridization target is a microarray, usually a glass slide, with DNA 
spots representing known genomic locations. After the hybridization of sample and 
reference DNA, microarrays are washed from unbound material and scanned with a 
laser scanner to form an image file for data analysis. The analysis is done with specific 
image analysis software that measures the signal intensities of the different colors in 
each spots and turns them into a signal ratio. Ratios obtained from different data spots 
are organized and visualized with ordered genomic locations and analyzed with the 
appropriate software. 
Three different types of microarray platforms, classified according to the type of 
DNA arranged on the microarray, have been used in aCGH applications: bacterial 
artificial chromosome (BAC), complementary DNA (cDNA), and oligonucleotide-
based microarrays (Table 1). The resolution of the different platforms is dependent on 
the size, number, and uniformity of the genomic distribution of the probes (Coe et al. 
2007). Depending on the platform used, the resolution of aCGH ranges from around 1 
Mb to a few Kbs. The moving average of signals from adjacent probes is used in cDNA 
and oligonucleotide analyses to reduce noise, whereas in BAC arrays it is not needed 
because of the large size of the individual clones. The possibility to design and 
manufacture specific oligonucleotide probes and the high probe densities in arrays 
obtained in industrial manufacturing make oligonucleotide arrays the platform with the 
highest resolution. Due to advances in analysis software development and microarray 
manufacturing processes, oligonucleotide microarrays are now the most commonly used 
microarrays. SNP-array, an oligonucleotide-based platform that can be used for the 
simultaneous analysis of copy number alterations and LOH, is reviewed in the next 
section. 
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A limitation of aCGH is that changes that do not affect the relative copy number, 
such as polyploidy and balanced translocations or inversions, are not detected. It has 
also been suggested that an alteration has to be present in at least 20-30% of cells in the 
sample to obtain proper resolution, and thus, aberrations that are present in only a small 
proportion of cells, e.g. in the case of minimal residual disease or mild mosaicism, are 
undetectable (Ballif et al. 2006, Gondek et al. 2008). 
Array-CGH has been widely used for the detailed analysis of gene copy numbers 
in cancers, leading to cancer classification proposals as well as the discovery of 
candidate genes with clinical significance (reviewed by Kallioniemi 2008). Various 
genome-wide aCGH techniques have also revealed that besides single-nucleotide 
polymorphisms also large-scale copy number polymorphisms (from 1 kb to 2 Mb in 
size) are common in the human genome (Iafrate et al. 2004, Sebat et al. 2004, Redon et 
al. 2006). The common existence of copy number polymorphisms is challenging in 
aCGH data analysis when polymorphisms and possibly disease-associated alterations 
need to be distinguished. However, copy number polymorphisms may also be 
associated with susceptibility to a disease. In fact, a proportion of copy number 
variations (CNVs) overlap with known disease genes (Redon et al. 2006). The CNV 
database, which is constantly updated with published CNV data, is available at 
http://projects.tcag.ca/variation/ and is helpful in interpreting aCGH data. 
 
 
3.2. Single-nucleotide polymorphism microarray analysis 
 
Various polymorphisms in the human genome, such as restriction fragment length 
polymorphism (RFLPs), microsatellites, and single-nucleotide polymorphisms (SNPs), 
have been utilized in the analysis of LOH. SNPs are the most common variation 
detected in the human genome, with over ten million known SNPs and over 3 million of 
these genotyped (The International Hapmap Consortium 2007, http://www.ncbi.nlm. 
nih.gov/snp). SNPs commonly have two alleles; thus, heterozygous and homozygous 
genotypes can be identified. Because SNPs are densely located in the genome, they 
provide an excellent basis for high-resolution and genome-wide microarray analysis. 
SNP-arrays, comprinsing oligonucleotide probes that indentify specific SNPs, 
were first designed for large-scale genotyping (Wang et al. 1998). Since then, the SNP-
array technology has been shown to be applicable for simultaneous detection of LOH 
and gene copy number alterations and also to have the ability to reveal UPD, a copy 
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number neutral LOH (Lindblad-Toh et al. 2000, Bignell et al. 2004, Raghavan et al. 
2005). 
In SNP-array analysis, only one DNA sample is labeled and hybridized to an 
array (Figure 1). The signal intensities obtained in the experiment reveal three possible 
genotypes for each SNP (AA and BB homozygotes, and an AB heterozygote). The copy 
number and LOH data can be produced in three ways. Firstly, cancerous and normal 
tissue of the same patient can be hybridized to separate arrays, with the data then being 
compared with computer analysis tools (Bignell et al. 2004, Zhao et al. 2004). 
Secondly, the analysis can be done by comparing the sample hybridization to a large set 
of reference hybridizations by using specific algorithms (Nannya et al. 2005). These 
reference data can be retrieved from databases, or a set of normal tissue hybridizations 
can be performed. The third option is to use an analysis tool, which requires no 
reference hybridizations, but is based on a mathematical model (Beroukhim et al. 2006). 
While in the aCGH analysis genomic DNA is successfully used as a sample, in 
SNP-array analysis the complexity of the human genome has been problematic because 
of cross-hybridizations and nonspecific signals (Kennedy et al. 2003, Matsuzaki et al. 
2004, Gunderson et al. 2005, Steemers et al. 2006). Assays to overcome these problems 
have been developed such as the whole genome sampling assay (WGSA) (Kennedy et 
al. 2003, Matsuzaki et al. 2004) and the whole genome genotyping (WGG) assay 
(Gunderson et al. 2005, Peiffer et al. 2006, Steemers et al. 2006). In WGSA analysis, 
the genome complexity is reduced to contain only relevant sequences by digestion of 
DNA with specific enzymes and subsequent selective amplification of the fragments of 
specific size (Kennedy et al. 2003, Matsuzaki et al. 2004). In the WGG protocol, four 
basic steps are performed: whole genome amplification, hybridization to capture probes 
on BeadChip (Illumina) microarray, SNP scoring with allele-specific primer extension, 
and signal amplification (Gunderson et al. 2005, Steemers et al. 2006). 
Developments in microarray technology have enabled production of SNP-arrays 
with a very high density. Commercial SNP-arrays with around one million SNPs are 
currently available for genomic analysis (http://www.affymetrix.com, 
http://www.illumina.com). Furthermore, SNP-arrays have proved to be efficient tools in 
genomic analysis of cancer since many studies have shown recurrent regions of copy 
number alterations, LOH, and UPD (Dutt & Beroukhim 2007, Tuna et al. 2009). 
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Table 1. Different platforms used in aCGH analyses. 
Platform Probe size Special characteristics
BAC 80-200 kb Sensitive to relatively large alterations
cDNA ~300 bp Represents coding sequence
Oligonucleotide 25-85 bp Industrial synthesis
Oligonucleotide SNP 21-85 bp Industrial synthesis, also reveals copy number neutral LOH  
 
 
 
 
 
 
 
Figure 1. Comparison of aCGH and SNP-array methods. In the aCGH experiment, sample and 
reference are labeled differently and hybridized together on one array. The ratio of signal intensities then 
shows the copy number profile. In the SNP-array experiment, sample and reference DNA are both 
similarly labeled and hybridized on separate arrays. The signal intensities of each SNP produce specific 
genotypic call (AA, AB, or BB). Sample and reference data are then compared with computer analysis 
tools and both copy number profile, and LOH regions can be detected. 
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4. Leukemia 
 
Leukemia is a disease characterized by clonal expansion of malignant blood cells. 
Leukemia is divided into acute and chronic types based on the maturity of the leukemic 
cells. Chronic leukemia can be asymptomatic or symptoms can be mild and slowly 
worsen. In acute leukemia, the symptoms appear rapidly and are more severe. 
Leukemias are also divided into myeloid and lymphoid types according to the malignant 
cell lineage. Leukemia can cause various symptoms that are common in many diseases, 
including fever, night sweats, frequent infections, weakness, fatigue, headache, pains in 
joints, bruising and bleeding, enlarged spleen, and swollen lymph nodes. Therefore, 
various tests are done to confirm the diagnosis. Distinguishing between different 
hematological malignancies is based on cell morphology, immunophenotyping, and 
cyto- and molecular genetic alterations (Swerdlow et al. 2008). Two different types of 
leukemia, AML and CLL, the two most common types in adults, were studied here and 
are described in more detail. 
 
 
4.1. Acute myeloid leukemia  
 
4.1.1. Clinical characteristics and treatment of acute myeloid leukemia 
 
In AML, myeloid blasts are clonally expanded in bone marrow and blood, and increased 
proliferation, reduced apoptosis, and lack of differentiation characterize the malignant 
cells (Lowenberg et al. 1999). AML is the most common acute leukemia in adults with 
a median age of 60-70 years and it is slightly more common in males than in females 
(Estey & Dohner 2006). Overall annual incidence of AML is approximately 3.8/100 
000 in people under 65 years of age and 17.9/100 000 in older populations (Estey & 
Dohner 2006). In Finland, approximately 120 AML cases are detected every year in 
adults (Elonen 2007). 
Etiology of AML is largely unknown, but associated factors include ionizing 
radiation, earlier cytotoxic chemotherapy, benzene exposure, and smoking (Smith et al. 
2004, Estey & Dohner 2006). Familial AML is very rare and little is known of the 
genetic background, although germline CEBPA mutations have been detected in some 
cases (reviewed by Owen et al. 2008, Pabst et al. 2008). Additionally, risk of AML is 
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increased in such conditions as Down syndrome, Fancony anemia, ataxia-telangiectasia, 
and Bloom syndrome because of increased genomic instability (Smith et al. 2004). A 
variable scale of symptoms mainly caused by burden of leukemic cells, abnormal 
marrow function, and tissue infiltration is detected in AML patients, including fever, 
fatigue, anemia, infections, and bleeding (Lowenberg et al. 1999, Smith et al 2004, 
Estey & Dohner 2006). 
At least 20-30% of blasts in marrow or blood are detected typically in the 
diagnosis of AML (Lowenberg et al. 1999, Smith et al 2004, Estey & Dohner 2006). 
The AML blasts are immature cells with round to oval nuclei and finely granular 
chromatin (Smith et al. 2004). Auer bodies, the rod-like structures that are formed of 
aggregates of normal granules are a specific finding in cytoplasm of blasts in one-third 
of cases (Smith et al. 2004). Two different classification systems categorize AML cases 
into subtypes. The French-American-British (FAB) classification is based on cell 
morphology and maturity and classifies AML into eight subtypes (M0 through to M7) 
(Bennett et al. 1976). A more novel system currently in use, the World Health 
Organization (WHO) system, divides AML into subtypes based on genetic and clinical 
factors (Table 2, Swerdlow et al. 2008). Immunophenotypic markers, such as CD45, 
CD34, CD117, and cytoplasmic myeloperoxidase, are analyzed in diagnosis of AML to 
identify the myeloid origin of blasts, and some markers (e.g. CD14, CD11b, 
glycophorin A, CD41, CD42, and CD 61) are also associated with specific lineage 
differentiation (Smith et al. 2004).  
AML is a genetically and clinically heterogeneous malignancy. Prognostic 
factors of AML include age, response to therapy, cytogenetics, and bone marrow blast 
count (Estey & Dohner 2006). Treatment of AML is commonly based on multidrug 
chemotherapy and allogeneic bone marrow stem cell transplantation (Lowenberg et al. 
1999, Estey & Dohner 2006). Although initial remission is often obtained, relapse is 
common. The five-year survival rate of young AML patients is 40-65% and elderly 
patients 10-15% depending on age and other prognostic factors (Derolf et al. 2009). The 
treatment of elderly patients has been problematic because chemotherapy causes severe 
side-effects and mortality (Estey & Dohner 2006, Kantarjian et al. 2008). 
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Table 2. WHO classification of acute myeloid leukemia. 
Categories Common associated chromosomal alterations
AML with recurrent genetic aberrations t(8;21)(q22;q22), inv(16)(p13q22), t(16;16)(p13;q22), t(15;17)(q22q12), 
t(9;11)(p22;q23)
AML with myelodysplasia-related alterations complex karyotype, -7/del(7q), -5/(del5q)
Therapy-related myeloid neoplasms complex karyotype, -7/del(7q), -5/(del5q), balanced translocations
AML, not otherwise categorized no  unique alterations
Data retrieved from Swerdlow et al. (2008).  
 
 
4.1.2. Genetic alterations in acute myeloid leukemia 
 
Approximately 200 recurrent chromosomal aberrations have been detected in 
cytogenetic analyses of AML (Mrozek et al. 2004). The most common cytogenetic 
changes are trisomy 8, t(8;21), t(15;17), inv(16), t(6;9), and t(8;16) (Table 3). Balanced 
reciprocal translocations typical for AML usually cause alterations in the function or 
transcription factors involved in myeloid differentiation or in tyrosine kinases (Dash & 
Gilliland 2001, Steffen et al. 2005). Despite the common existence of translocations in 
AML, they are seen only in a small proportion (20%) of patients (Heim & Mitelman 
2009). Other characteristic chromosome changes of AML, detected as a sole alteration 
or in association with other changes, include +4, +8, +11, +13, +19, +21, -5, and -7 
deletions in 5q, 7q, and 9q and various alterations involving 11q23 (Heim & Mitelman 
2009). Of the relatively rarely detected amplifications in AML, the most common 
regions and genes include MYC in 8q24 (Alitalo et al. 1985, Thomas et al. 2004) and 
MLL in 11q23 (Allen et al. 1998, Ariyama et al. 1998, Poppe et al. 2004). Complex 
karyotype with three or more alterations, in the absence of the common translocations, 
is detected in 10% of AML patients. Furthermore, in standard cytogenetic analysis, 40-
50% of AML remain karyotypically normal (Grimwade et al. 1998, Byrd et al. 2002, 
Heim & Mitelman 2009). The molecular pathogenesis of the complex karyotype group 
of patients as well as karyotypically normal patients is largely unknown. Cytogenetic 
and genetic alterations are considered important prognostic factors in AML. Based on 
cytogenetic alterations, AML patients can be divided into three risk groups; poor, 
intermediate, and favorable (Grimwade et al. 1998, Slovak et al. 2000, Grimwade et al. 
2001, Byrd et al. 2002, Table 4). 
A number of mutated genes have been described in the pathogenesis of AML 
(Table 5). Many of the commonly mutated genes in AML are involved in cell 
proliferation, myeloid differentiation, cell cycle regulation, and apoptosis (Renneville et 
al. 2008). Since the fusion genes detected commonly in AML cannot alone cause the 
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pathogenesis, some of these mutated genes have been suggested to be the second hit 
needed. For example, mutations of the tyrosine kinase gene KIT are often associated 
with inv(16) or t(8;21) (Beghini et al. 1998, Gari et al. 1999, Wang et al. 2005).  
The large normal karyotype group of AML is a heterogeneous entity at the 
molecular level, and although the prognosis is intermediate compared with other 
cytogenetic groups, there is also variation in the clinical course (Mrozek et al. 2007). 
Although part of the heterogeneity is explained by frequently detected gene mutations, 
the mutations detected to date have not been shown to cause the leukemogenesis solely 
(Mrozek et al. 2007). FLT3 and NPM1 mutations are detected most often in 
karyotypically normal AML cases. FLT3 ITD mutations are detected in 28-33%, FLT3 
tyrosine kinase domain point mutations in 5-10%, and NPM1 mutations in 40-60% of 
cases (Falini et al. 2005, Thiede et al. 2006, Mrozek et al. 2007). Besides mutations, 
altered gene expression of BAALC, ERG, and MN1 has been associated with prognosis 
in karyotypically normal AML patients (Baldus et al. 2007, Mrozek et al. 2007). Cryptic 
gene copy number alterations might explain some of the heterogeneity, but in 
karyotypically normal AML, FISH and cCGH have uncovered cryptic alterations only 
occasionally (Dalley et al. 2002, Frohling et al. 2002). 
Microarray methods have in recent years been used to analyze the AML 
genome. Array-CGH studies with BAC arrays have revealed cryptic alterations in AML 
patients with known karyotypic alterations (Baldus et al. 2004, Tchinda et al. 2004, 
Paulsson et al. 2006, Rucker et al. 2006), oligonucleotide aCGH was in one study able 
to reveal cryptic alterations in 60% of  karyotypically normal AML cases (Suela et al. 
2007), and SNP-array analyses have shown UPD in 10-20% of karyotypically normal 
AML (Gorletta et al. 2005, Raghavan et al. 2005). Recently, frequent UPD and cryptic 
copy number alterations have been detected in larger patient cohorts of MDS and AML 
using 250K SNP-array (Dunbar et al. 2008, Gondek et al. 2008). In addition, acquired 
UPD regions have been found to harbor homozygous mutations of FLT3, WT1, CEBPA, 
RUNX1, and CBL (Fitzgibbon et al. 2005, Griffiths et al. 2005, Dunbar et al. 2008). 
Improvements in prognostic classification based on gene expression profiling have also 
been suggested (Bullinger et al. 2004, Valk et al. 2004). 
Although many recurrent chromosomal alterations in AML are known, many of 
the target genes remain obscure. More than one genetic alteration is needed in AML 
pathogenesis since many alterations are insufficient alone to cause leukemia, reflecting 
the multistep nature of cancer. Classification of AML according to genetic changes to 
the prognostic subgroups and development of targeted therapies to various genetic 
subgroups continue to be important research goals. 
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Table 3. Common cytogenetic alterations in acute myeloid leukemia. 
Alteration Frequency (% ) among cytognetically 
aberrant casesa
Target genes
trisomy 8 15 Not known
t(8;21) 7 RUNX1-RUNX1T1
t(15;17) 5 PML-RARA
inv(16), t(16;16) 4 CBFB-MYH11
11q23 alterations 7-8 MLL
t(6;9) 0.5 DEK-  NUP214
inv(3), t(3;3) 1 EVI1
t(8;16) 0.5 MYST3-CREBBP
afrequencies obtained from Heim & Mitelman (2009).  
 
 
 
 
Table 4. Prognostic risk groups in acute myeloid leukemia based on cytogenetics. 
Risk group Cytogenetic alterations 
Favorable t(8;21), inv(16), t(15,17)
Intermediate Normal karyotype, +8, +21,+22, del(7q), del(9q), 11q23 alterations
Poor Complex karyotype, -5,-7, del(5q)
Data based on Grimwade et al. (1998).  
 
 
 
 
Table 5. Common mutated genes in acute myeloid leukemia. 
Gene  Location References
FLT3 13q12 Nakao et al. (1996), Yamamoto et al. (2001), Thiede et al. (2002 )
NPM1 5q35 Falini et al. (2005), Thiede et al. (2006)
MLL 11q23 Schichman et al. (1994), Dohner et al. (2002)
NRAS 1p13.2 Janssen et al. (1987), Bowen et al. (2005)
KRAS 12p12.1 Bowen et al. (2005)
KIT 4q11-q12 Beghini et al. (1998), Gari et al. (1999)
CEBPA 19q13.1 Pabst et al. (2001), Preudhomme et al. (2002)
RUNX1 21q22.3 Osato et al. (1999), Preudhomme et al. (2000)
WT1 11p13 King-Underwood et al. (1996), King-Underwood & Pritchard-Jones (1998)
TP53 17p13 Fenaux et al. (1991), Slingerland et al. (1991)  
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4.2. Chronic lymphocytic leukemia 
 
4.2.1. Clinical characteristics and treatment of chronic lymphocytic leukemia 
 
CLL is characterized by clonal proliferation and accumulation of mature B-lymphocytes 
in the blood, bone marrow, and lymphoid tissue. CLL cells have experienced antigen 
stimulation and the malignancy has been proposed to originate from memory B-cells, 
naïve B-cells, or marginal-zone B-cells (reviewed by Chiorazzi et al. 2005, Kuppers 
2005). CLL is the most common adult leukemia in developed countries, having a 
median age of onset of 65 years. It is more common in males, with a 2:1 male female 
ratio (Jaffe et al. 2001). The annual incidence of CLL is 3.5/100 000 in the US and 1.3-
13.7/100 000 in Europe (reviewed by Dighiero & Hamblin 2008). In Finland, slightly 
more than 100 CLL cases are diagnosed every year (Ruutu 2007). 
The etiology of CLL remains unknown, with no associations reported with viral 
infections, chemicals, or radiation (reviewed by Chen & McMillan 2008). Age-related 
events, such as an increase of DNA damage by reactive oxygen species, a decline in B-
cell production associated with defective B-cell receptor signaling, decrease in T-cell 
immunity causing defects in elimination of aberrant B-cells, and chronic stimulation by 
an antigen, are also suggested to affect CLL pathogenesis (Chen & McMillan 2008). In 
subset of patients, inherited susceptibility may also play a role in CLL development. 
Family studies have revealed that genetic susceptibility is detected in approximately 5-
10% of CLL patients (Houlston et al. 2002, Rawstron et al. 2002, reviewed by Goldin & 
Caporaso 2007). However, the exact CLL susceptibility genes remain unknown. 
Generally, CLL progresses slowly, but the disease type can vary greatly from 
asymptomatic to a more serious form with various symptoms. Symptoms of CLL 
include lymphadenopathy, fatigue, night sweats, weight loss, anemia, and infections 
(Hallek et al. 2008). However, approximately 70-80% of CLL cases are found 
incidentally in a routine full blood count (Dighiero & Hamblin 2008) Diagnosis of CLL 
is based on detection of characteristic small and mature lymphocyte morphology, 
characteristic immunophenotype, and a blood lymphocyte count of over 5x109/L (or 
3x109/L if the cell morphology is mature) (Hallek et al. 2008). Although there is no 
specific immunophenotypic marker for CLL, a combination of markers is characteristic 
for CLL. Typical markers for CLL include low-density surface membrane 
immunoglobulin, CD5+, CD19+, CD20+, CD23+ FMC7 -/+, and CD22-/+ (Hallek et 
al. 2008).  
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WHO classification groups CLL with mature B-cell neoplasms together with 
small lymphocytic lymphoma (Swerdlow et al. 2008). Differentiation diagnostics of 
CLL from other lymphoproliferative diseases is based on morphology, 
immunophenotype, and recently also genetic markers (Swerdlow et al. 2008). 
Traditionally, Rai (Rai et al. 1975) and Binet (Binet et al. 1977, Binet et al. 1981) 
staging systems, which are based on clinical and cytological findings, have been used to 
predict prognosis of CLL patients; these classification systems classify CLL cases as 
early, intermediate, or advanced stage. 
Various prognostic factors are considered when making treatment choices for 
CLL patients. The prognostic factors that are currently considered important in CLL 
include age, stage, gender, performance, tumor burden, disease activity, specific serum 
parameters, and genetic aberrations (reviewed by Dohner & Stilgenbauer 2006, Seiler 
2006). Generally, asymptomatic patients survive without treatment, while chemo- and 
immunological therapies are used in advanced or more aggressive disease (Auer et al. 
2007, Dighiero & Hamblin 2008, Hallek et al. 2008). In young patients with aggressive 
disease, curation can be achieved with allogeneic transplantation (Gribben 2008). 
Although remission is often obtained with the current therapies, most of the patients 
relapse; thus, the treatment of CLL is rarely curative (Auer et al. 2007, Dighiero & 
Hamblin 2008). Since treatment of early and stable disease is not currently beneficial, 
markers that would help to reveal the cases that will develop into more aggressive forms 
of CLL are needed. 
 
 
4.2.2. Genetic alterations in chronic lymphocytic leukemia 
 
CLL cells have low mitotic activity in vitro. Before optimized mitogen stimulation was 
developed for karyotyping of CLL, obtaining mitoses of good quality and, more 
importantly, obtaining mitoses representing malignant cells was problematic (Knuutila 
et al. 1986). With karyotyping methodology using mitogen stimulation, chromosomal 
alterations are detected in 40-50% of CLL cases (Juliusson et al. 1990). The 
development of other cytogenetic techniques has increased the number of alterations 
detected. Especially interphase FISH, targeted to the most commonly altered regions, 
has proved to be useful in diagnostic analyses of CLL and can reveal alterations in 80% 
of cases (Dohner et al. 2000). Also cCGH has revealed additional new aberrations in 
CLL (Bentz et al. 1995, Bea et al. 2002). In contrast to other hematological 
malignancies, translocations are rare in CLL (Stilgenbauer et al. 2002, Guipaud et al. 
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2003). The prognostically significant copy number alterations in CLL include the 
unfavorable deletions of 11q22-23 and 17p and the favorable deletion of 13q14.3 
(Dohner et al. 2000, Table 6). Trisomy 12 is among the common chromosomal 
alterations of CLL, but its prognostic significance has not yet been clarified (Krober et 
al. 2002, Oscier et al. 2002, Oscier et al. 2004, Table 6). 
Despite extensive studies, only a few target genes with mutations in the 
frequently altered chromosomal regions have been suggested, such as TP53 in 17p 
(Gaidano et al. 1991, Fenaux et al. 1992), ATM in 11q (Stankovic et al. 1999), and 
micro-RNA genes MIR15A and MIR16-1 in 13q14.3 (Calin et al. 2002). Other recurrent 
cytogenetic changes in CLL include deletion of 6q21 and gains of 12q, 8q, and 3q 
(Heim & Mitelman 2009). Target genes of these regions and many other chromosomal 
alterations in CLL remain unknown. 
The TCL1 gene located in 14q31.2 may play an important role in CLL 
pathogenesis. It is overexpressed in aggressive forms of CLL (Pekarsky et al. 2006, 
reviewed by Calin et al. 2007). MicroRNAs MIR29 and MIR181 have also been 
discovered to inhibit TCL1 expression and to often be downregulated in patients with 
high TCL1 expression (Pekarsky et al. 2006, reviewed by Calin et al. 2007). In addition, 
mutations have been found in TCL1 in CLL (Pekarsky et al. 2008). 
Besides chromosomal alterations, immunoglobulin variable heavy chain (IgVH) 
gene mutation status is considered to be an important prognostic marker. IgVH gene 
hypermutation is detected in approximately half of CLL patients and indicates favorable 
outcome, while patients with unmutated status have worse prognosis (Damle et al. 1999, 
Hamblin et al. 1999). Expression of ZAP70 and CD38 were suggested to be surrogate 
markers for VH mutation status (Chen et al. 2002), but have in later studies provided 
controversial results (Stilgenbauer et al. 2002, Seiler et al. 2006). 
Microarray analyses have also been used to characterize the CLL genome. 
Although CLL is a heterogeneous disease, gene expression microarray profiling studies 
have shown that CLL has a characteristic expression signature that is different from 
other lymphoid malignancies (Klein et al. 2001, Rosenwald et al. 2001). Based on gene 
expression, CLL cases can also be clustered into subgroups with specific genetic 
alterations (Haslinger et al. 2004, Kienle et al. 2005). With aCGH and SNP-array 
methods, common CLL specific alterations as well as novel imbalances have been 
detected with high resolution, suggesting that these techniques could be used in clinical 
diagnostics of CLL (Schwaenen et al. 2004, Pfeifer et al. 2007). 
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Table 6. The most common chromosomal alterations in chronic lymphocytic leukemia. 
Aberration Prognosis Suggested target genes
-13q14 favorable MIR15A , MIR16-1
-11q22-23 unfavorable ATM
trisomy 12 controversial -
-17p13 unfavorable TP53  
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AIMS OF THE STUDY 
 
The aim of this study was to analyze chromosomal imbalances in AML and CLL using 
recent microarray technologies, including aCGH and SNP-array analyses, and to 
characterize the genomic alterations that potentially have a role in leukemogenesis. 
Specific objectives were the following:  
 
• To characterize marker chromosomes and 11q amplicons in AML. 
• To screen cryptic copy number alterations in karyotypically normal AML and 
CLL. 
• To characterize known chromosomal alterations with aCGH to uncover 
minimal altered genomic regions and altered genes. 
• To screen LOH, including UPD, with SNP-arrays from karyotypically normal 
AML.  
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MATERIALS AND METHODS 
 
1. Specimens (I-IV) 
 
1.1. Acute myeloid leukemia specimens 
 
Specimens from AML patients that were diagnosed and treated in Helsinki University 
Central Hospital were analyzed in Studies I, II, and IV (Table 7.). DNA was extracted 
from bone marrow samples (Studies I, II, and IV) or blood samples (Study I) with 
standard methods. For the FISH analysis, fixed bone marrow cells or archival G-
banding slides were used. RNA extracted from bone marrow mononuclear cells was 
used in Study I. Samples were collected with informed consent from patients and 
approval from the HUS Ethics Committee, Department of Medicine, Helsinki, Finland. 
 
 
1.2. Chronic lymphocytic leukemia specimens 
 
CLL patients in Study III were diagnosed and treated at Tampere University Hospital. 
Clinical details of these patients have previously been published (Koski et al. 2000, 
Karhu et al. 2003). Archival DNA samples extracted from CLL cells were used for the 
analyses (Table 7). Samples were collected with informed consent from patients and 
approval from the Tampere University Hospital Ethics Committee. 
 
 
Table 7. Specimens and studies. 
Study n Age*/Median 
age (range)**
Female/male Leukemia 
type
Microarrays used
I 2 14 & 38 * 0/2 AML cDNA, oligonucleotide
II 26 49 (21-75) ** 10/16 AML oligonucleotide
III 20 67 (48-79) ** 7/13 CLL oligonucleotide
IV 19 49 (21-74) ** 7/12 AML SNP  
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2. Complementary DNA array comparative genomic 
hybridization (I) 
 
Analysis with cDNA aCGH was used in Study I in two cases of AML. Agilent human 1 
cDNA microarray (Agilent Technologies, Palo Alto, CA, USA) containing 13 000 
cDNA features genome-wide was used in the experiments. DNA extracted from pooled 
peripheral blood of healthy males was used as a reference. Digestion, labeling of 
sample, and reference genomic DNA with separate colors, hybridization, and washing 
of slides were done as described by Atiye et al. (2005), with minor modifications. 
Briefly, a digested (AluI and RsaI, Sigma, St. Louis, MO, USA) and phenol-chloroform-
purified DNA sample (6 µg) was labeled by random labeling with the RadPrime DNA 
labeling system (Gibco BRL, Gaithersburg, MD, USA) using Cy5-dUTP for sample 
DNA and Cy3-dUTP for reference DNA (Amersham Pharmacia, Piscataway, NJ, 
USA). Hybridization was performed at 65˚C for 16-17 h, and slides were washed for 3-
5 min at room temperature in each of three different solutions (0.1% SDS, 
0.5xSSC/0.01% SDS, and 0.06xSSC). Slides were scanned with the Agilent microarray 
scanner G2565AA (Agilent Technologies) and microarray image analysis was done 
with Feature Extraction software version 7.5 (Agilent Technologies) using Lowess 
normalization. Data analysis was then performed with Microsoft Excel. Poor-quality 
features, flagged by Feature Extraction software were removed. The Log2 ratio 
calculated from the green and red signal intensities was then plotted with chromosomal 
bp locations (April 2003 freeze, University of California-Santa Cruz genome browser; 
http://genome.ucsc.edu/) to create the copy number profiles.  
 
 
3. Oligonucleotide array comparative genomic hybridization 
(I-III) 
 
Chromosomal alterations in AML were analyzed in Studies I and II and in CLL in 
Study III by using oligonucleotide aCGH. Agilent 44K CGH oligonucleotide 
microarray with ~44 000 60-mer oligonucleotide probes (Agilent Technologies, Santa 
Clara, CA, USA) was used in the experiments. Reference DNA from pooled blood of 
healthy males or females was used in hybridizations. DNA samples were digested, 
labeled, hybridized, and washed according to Agilent's protocols, and slides were 
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scanned with Agilent's microarray scanner G2565AA (Agilent Technologies). Image 
analysis was performed with Agilent's Feature Extraction 7.5 (Study I) or 8.1 (Studies II 
and III) software with linear and Lowess normalizations and background corrections. 
Data were analyzed and visualized with CGH Analytics software (Agilent 
Technologies), with the genomic locations retrieved from NCBI build 35, May 2004 (hg 
17). 
 
 
4. Fluorescence in situ hybridization (I, II) 
 
Some of the aCGH findings were further characterized and validated in AML in Studies 
I and II using fluorescence in situ hybridization (FISH). Commercial probes from Vysis 
Inc. (Vysis, Downers Grove, IL, USA) were used in all of the experiments. The LSI 
MLL dual color probe was used in Study I to analyze amplifications in 11q, the LSI 
MYC dual color break-apart probe in Study II to analyze amplifications detected in 
8q24.13-24.21, and the LSI TEL-AML1 ES dual color translocation probe in Study II to 
analyze ETV6 (TEL) loss in 12p13.2. If available, methanol-acetic acid fixed cells were 
used to prepare the metaphase slides for FISH analysis. When fixed cells were 
unavailable, archival G-banding slides were used. The protocol according to Skacel et 
al. (2001) was applied. In brief, cover slips were removed by soaking the slides several 
days in xylene. Slides were then washed with fresh xylene and two descending ethanol 
series (100% - 95% - 80%). Finally, 0.5% HCL-70% ethanol wash was used to remove 
the old staining. Vysis instructions for locus-specific FISH were followed. Briefly, after 
formamid denaturation and cold alcohol washes, the hybridization was done by 
incubation overnight at 37˚C. Post-hybridization washes with 0.4xSSC/0.3% Igepal (2 
min) and 2xSSC/0.1% Igepal (5 s-1 min) were performed. Analysis of the results was 
done with an Axioplan 2 microscope (Carl Zeiss, Oberkochen, Germany). Images were 
captured with Isis software (Metasystems, Altlussheim, Germany). Analysis was based 
on ~50 metaphases, and if insufficient proper metaphases were available, interphases 
(~400) were analyzed. 
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5. Gene expression (I) 
 
In Study I, gene expression of amplified genes in one AML case was analyzed using 
Agilent human 1 cDNA microarray (Agilent Technologies, Palo Alto, CA, USA). 
Patient RNA extracted from mononuclear cells of bone marrow was hybridized with 
reference RNA from pooled cancer cell lines. Labeling, hybridization, and washing 
were done according to the manufacturer’s instructions. Scanning was performed with 
Agilent's microarray scanner G2565AA (Agilent Technologies) and image analysis with 
Feature Extraction 7.5 using Lowess normalization. Poor-quality data was filtered out, 
and the log2 ratio was calculated from the signal intensities. A threshold of log2 ratio 
over 1.00 was selected for overexpression. 
 
 
6. Mutation analysis (II) 
 
In Study II, FLT3 and NPM1 mutations were analyzed in AML. Two types of FLT3 
mutations, internal tandem duplication (ITD) in the juxtamembrane domain and D835 
point mutation in the tyrosine kinase domain activation loop, were analyzed with the 
FLT3 Mutation Assay kit for gel detection (In VivoScribe Technologies, San Diego, 
CA, USA), following the manufacturer’s instructions. Exon 12 mutations of NPM1 
were analyzed by PCR and sequencing using the following primers: NPMseqF, 5’-
gttaactctctggtggtagaatgaa-3’, and NPMseqR, 5’- aaaaggacagccagatatcaac-3’, and 
standard protocols. Sequencing was done using the BigDyeTerminator kit (Applied 
Biosystems Inc, Foster City, CA, USA) and ABI Prism 3130xl Genetic Analyzer 
(Applied Biosystems Inc). 
 
 
7. Loss of heterozygosity analysis with single-nucleotide 
polymorphism microarray (IV) 
 
In Study IV, SNP-array experiments were performed in AML cases using GeneChip 
Human Mapping 50K Array Xba 240 (Affymetrix, Inc., Santa Clara, CA, USA) 
according to the manufacturer’s protocol. Washing and staining of arrays were done 
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using the Affymetrix Fluidics station 450, and scanning was performed with the 
Affymetrix GeneChip Scanner 3000. Images were analyzed with GeneChip operating 
software GCOS (Affymetrix, Sacramento, CA, USA), and genotype data were obtained 
with GTYPE 4.1 software (Affymetrix) using the dynamic model algorithm. Reference 
data, obtained from the international HapMap project’s homepage 
(http://www.hapmap.org/), comprised data of 46 HapMap CEPH females. LOH and 
DNA copy numbers were analyzed with the CNAT4 tool (Affymetrix) and CNAG2.0 
software (Nannya et al. 2005). The log2 copy number ratios were also imported to CGH 
analytics software (Agilent Technologies, Palo Alto, CA, USA) for visualization and 
comparison with oligonucleotide aCGH data of the same patients. 
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RESULTS AND DISCUSSION  
 
1. Characterization of 11q amplicons in acute myeloid 
leukemia (I)  
 
Sometimes unidentified fragments of chromosomal material are detected with 
karyotyping. These fragments are called marker chromosomes in the cytogenetic 
nomenclature. Marker chromosomes may be composed of specific amplified segments 
from one chromosome, but can also have complicated structures that are formed from 
material of several chromosomes. Our two studies (I and II) demonstrated the value of 
aCGH in combination with other cytogenetic techniques in defining the marker 
chromosomes and amplified candidate oncogenes. Because aCGH shows only a relative 
copy number change compared with a normal genome and does not show the structural 
form of the change, it can not be used as the sole basis for an analysis of 
extrachromosomal markers. It reveals, for example, that certain genes are amplified, but 
it fails to show whether it is an hsr inside the chromosome or a dmin. However, aCGH 
does identify the unknown amplified genes with high resolution, and their location and 
chromosomal structures can then be visualized using locus-specific FISH or M-FISH, 
which shows each chromosome with a specific color. 
Alterations in 11q are relatively common in AML. The best clarified gene in 11q 
is the MLL, which is known to form fusion genes with over 70 different partners 
(Harper & Aplan 2008). Additionally, many different breakpoints and losses and gains 
of copy number have been detected in 11q in AML (Tanaka et al. 2001). 
Characterization of the amplicons in two AML cases with marker chromosomes by 
various methods in Study I revealed two different types of 11q amplicons. 
We characterized a complex amplicon pattern in one case, associated with the 
MLL-ARHGEF12 (MLL-LARG) fusion gene, in 11q23.3-q25 (Figure 2). The amplicon 
was composed of two distinct amplicons (1.2 Mb and 13.3 Mb) and a small deleted 
sequence (1.9 Mb) in between. The proximal breakpoint could be defined to be in the 
middle of MLL and the distal breakpoint in the middle of ARHGEF12. With MLL dual 
color FISH probe (Vysis), which marks with red signal the distal part and with green 
signal the proximal part of the MLL, normal red and green signals were detected in one 
homologous chromosome 11. The other homologous chromosome lacked the red signal, 
and only green signals were detected in marker chromosomes. These results confirmed 
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deletion of the distal part and amplification of the proximal part of the MLL. In 
addition, the case II also had a small distinct gain in 11q22. With the high-resolution 
oligonucleotide aCGH, the sizes of the altered regions and genes involved in the 
amplified and deleted regions in 11q could be identified. Although exact mechanisms 
involved in the formation of amplicons and fusion genes remain obscure, breakages in 
fragile sites have been suggested to be involved in initiating these events (reviewed by 
Myllykangas & Knuutila 2006). Since fragile sites in 11q22.3 are known (reviewed by 
Popescu 2003), they might have been also involved in the mechanisms that led to the 
formation of the complex amplicon and MLL-ARHGEF12 fusion in our study case. 
Several genes in 11q besides MLL could be involved in the pathogenesis. Besides the 
MLL-ARHGEF12 oncogene, the deletion leading to the fusion gene formation might 
also have contained a tumor suppressor, one potential candidate being CBL.  
Additionally, other oncogenes could be located in the amplified regions. 
In the other patient, an additional ring chromosome, which consisted of 
chromosome 11 material, was seen with M-FISH. The amplicon did not include the 
MLL gene, and aCGH was done to detect the amplified region in detail. CDNA-based 
aCGH analysis showed continuous 5.5-Mb high-level amplification in 11q24.3-q25 
telomeric to MLL. Furthermore, the amplicons of the two cases analyzed in the Study I 
were overlapping, and we were able to define a minimal common region with additional 
candidate genes in 11q besides MLL. The common region contained 14 genes (FLI1, 
KCNJ1, KCNJ5, RICS, BARX2, NFRKB, APLP2, ST14, ADAMTS8, SNX19, NTM, 
OPCML, JAM3, and NCAPD3). Based on gene expression analysis, the most probable 
candidates of these were FLI1, NFRKB and SNX19 since they were highly 
overexpressed. In previous studies 11q amplifications not involving MLL have been 
detected (Nacheva et al. 1993, Rossbach et al. 1998, Crossen et al. 1999, Sait et al. 
2002). The amplified candidate genes in 11q aberrations telomeric to MLL include 
ETS1 (Rovigatti et al. 1986, Crossen et al. 1999, Yoshida et al. 1999, Sait et al. 2002), 
FLI1, SRPR, NFRKB, and KCNJ5 (Crossen et al. 1999), some of the previous studies 
thus supporting our target gene suggestions.  
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Figure 2. Array-CGH profile of chromosome 11 (upper panel) showing the structure of the amplicon and 
a loss within. In the lower panel, the marked region in a zoomed view shows the genes in the breakpoint 
of the deletion (circled), the MLL and ARHGEF12 (LARG), which form the fusion gene.  
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2. Cryptic copy number changes in karyotypically normal 
acute myeloid leukemia (II) 
 
It has been estimated that only alterations larger than 5 Mb can be detected in standard 
G-banding (Salman et al. 2004). In Study II, oligonucleotide (44K) aCGH showed 
cryptic copy number alterations in 4/26 of karyotypically normal acute myeloid 
leukemia cases (15%). The detected cryptic alterations were 0.4-4.1 Mb in size, 
showing the improved resolution of aCGH relative to G-banding. Three cases each 
harbored one loss. These losses were located in 8q24.11, 12p12.3, and 12p13.2. One 
patient had a more complex pattern of alterations, including two losses (1q41 and 
18q21.32), one gain (3p21.3), and one high-level amplification (8q24.13-q24.21, Figure 
3). Besides novel candidate genes, some known cancer genes detected previously in 
AML, namely ETV6 (reviewed by Bohlander 2005) and MYC (Alitalo et al. 1985, 
Thomas et al. 2004), were also detected and confirmed with FISH analysis.  
When the case with the 8q24.13-q24.21 amplicon was further analyzed with 
FISH, it was shown that the MYC oncogene was amplified extrachromosomally (Figure 
3). The re-evaluation of the G-banding slides showed very small, hardly detectable 
particles in some of the metaphases that had escaped detection in the diagnostic 
analysis. These particles, according to their size (4.1 Mb) that could be deduced from 
the aCGH results, were small episome-like, double minute chromosomes. In the 
amplicon, the following potential target genes besides MYC were also detected: TRIB1, 
FAM84B, PVT1, and CCDC26. A similar minimal common region has previously been 
detected with FISH in AML (Storlazzi et al. 2004, Storlazzi et al. 2006), and it has been 
suggested that MYC might not be the target gene because it has not been highly 
overexpressed (Storlazzi et al. 2004, Rucker et al. 2006, Storlazzi et al. 2006). The 
episome model of amplification, which explains the episome formation through a 
deletion mechanism, has been proposed to be involved in MYC amplification in AML 
(Storlazzi et al. 2006). Episomes have also been speculated to turn into dmins by 
growing and then possibly integrating with chromosomes to form hsrs (Carroll et al. 
1988, Von Hoff et al. 1988, Von Hoff et al. 1990). Because of the very small-sized 
dmins, our case might illustrate events in the episomal amplification mechanism where 
episomes have started to become dmins. 
Small extrachromosomal markers are relatively rarely detected in karyotypic 
analysis and require a skillful eye to detect them. The advantage of aCGH is that it can 
discover these types of amplifications without prior knowledge of their existence. 
Submicroscopic amplifications could be more common in leukemia than previously 
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thought and can be increasingly detected with high-resolution techniques such as 
aCGH. Besides the case in our study, an other example of the cryptic amplicon detected 
in leukemia with FISH and aCGH but not with karyotyping is the 500-kb episomal 
NUP214-ABL1 amplification found in acute lymphoblastic leukemia (Graux et al. 
2004). 
Mutations of FLT3 and NPM1 were also analyzed since they are relatively 
frequent alterations in karyotypically normal AML and also have prognostic 
significance (reviewed by Mrozek et al. 2007). FLT3 internal tandem duplications (ITD) 
were detected in 33%, tyrosine kinase domain activation loop point mutations in 21%, 
and NPM1 mutations in 57% of analyzed cases. Only one of the four cases with cryptic 
alterations detected with aCGH had mutations in FLT3 or NPM1. Mutations can be used 
as MRD markers in follow-up of karyotypically normal AML patients, but if they are 
not detected, the information of cryptic copy number alterations could be valuable when 
MRD markers are needed. 
After the publication of our results of AML, an other aCGH study of a larger 
cohort of patients from all cytogenetic subgroups described cryptic changes in 60% of 
karyotypically normal AML cases (Suela et al. 2007). Together with our study, these 
results show that although no specific recurrent and cryptic copy number alteration has 
been detected that would characterize the karyotypically normal group of patients, 
cryptic copy number alterations are relatively common in karyotypically normal AML. 
 
 
 
 
 
Figure 3. The left panel shows the aCGH profile of the amplification in 8q24.13-q24.21 (4.1 Mb in size), 
and the right panel the extrachromosomal amplification of MYC detected with FISH in the same patient. 
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3. Array comparative genomic hybridization in chronic 
lymphocytic leukemia (III) 
 
Despite the numerous known chromosomal alterations in CLL, only a few tumor 
suppressor or oncogenes have been described. Array-CGH is an effective tool for 
screening candidate oncogenes and tumor suppressors. In Study III, we analyzed 20 
CLL cases by using Agilent 44K oligonucleotide CGH microarray and detected new 
cryptic alterations not visible with standard karyotyping in three cases. We also 
analyzed the breakpoints and genes involved in known chromosomal alterations 
detected previously with other cytogenetic methods. Losses are the most commonly 
detected chromosomal alterations in CLL (Caporaso et al. 2007, Dighiero & Hamblin 
2008), and the alterations detected in our study followed the same trend.  
Cryptic changes were detected in both karyotypically normal and aberrant cases. 
The novel changes were located in 1q23.2-q23.3, 3p21.31, 16p13.3-pter, 17p13.2-p13.3, 
17q25.3-qter, and 22q11.22, providing new candidate genes. One of the most interesting 
cryptic findings was the 17p alteration telomeric to the TP53 gene, which was found in 
one case, suggesting other possible target genes beside TP53 in 17p deletions.  
The 13q14 deletion was the most common alteration, detected with aCGH in 
half of the cases (Figure 4). Sizes of the 13q deletions varied between 0.79 Mb and 
29.33 Mb. In six cases, losses in 13q14 were not detectable with G-banding and cCGH, 
but could be detected with aCGH, showing the superior resolution of this method. The 
exact breakpoints could be determined and a minimal common region of 158 kb 
harboring the suggested target microRNA genes MIR15A and MIR16-1 (Calin et al. 
2002) was identified. Homozygous deletions were detected in the minimal common 
region in some cases, thus possibly inactivating both alleles of the target genes. In the 
pathogenesis of CLL, microRNA genes have been proposed to have an important role 
(reviewed by Caligaris-Cappio et al. 2008).  
The second most common finding was losses in 11q (Figure 4); the losses were 
relatively large in size, 7.44 Mb being the smallest. This region also included one of the 
few suggested target genes in CLL, the ATM, which is a tyrosine kinase gene possibly 
involved in pathogenesis by participating in regulation of TP53 (reviewed by Dighiero 
& Hamblin 2008). However, several other genes in 11q22-23 can be involved in the 
pathogenesis such as NPAT, CUL5, and PPP2R1B (Kalla et al. 2007). 
Aberrations were detected with aCGH in our study in 70% of cases. The 
analyzed patient cohort included a large number of patients with normal karyotype by 
G-banding and cCGH (11 cases). With aCGH, we detected most of the known copy 
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number changes detected with G-banding or cCGH, and, furthermore, discovered some 
novel cryptic changes. Previously, chromosomal changes have been found in 80% of 
CLL cases by using FISH (Dohner et al. 2000). The percentage of the detected 
alterations is lower in our study, probably because we had in sample selection preferred 
normal karyotypic cases that would most likely have important cryptic alterations. In 
addition, with more high-resolution platforms such as Agilent 244k (Agilent 
technologies, http://www.agilent.com), even more alterations would likely have been 
revealed. For example, one of the CLL cases that had 13q loss detected by FISH but 
showed normal karyotype in 44k aCGH analysis was hybridized to the Agilent 244k 
array and a small 13q deletion was detected (unpublished data). 
Array-CGH has shown its ability to detect alterations previously detected only 
by FISH and also overcomes the problems that may arise with CLL in cell culturing and 
mitosis-dependent G-banding analysis. Array-CGH has therefore been suggested for 
diagnostic analysis of chromosome imbalances in CLL (Schwaenen et al. 2004, Pfeifer 
et al. 2007). In addition, some novel alterations have been detected with aCGH, such as 
a gain of MYCN in 2p24 (Schwaenen et al. 2004), and the new cryptic deletions in our 
study. 
 
 
 
 
Figure 4. Most recurrent deletions in chromosomes 11 and 13, detected using aCGH (figures prepared by 
using progenetix software, www.progenetix.net). 
 
 
44 
 
4. Loss of heterozygosity in karyotypically normal acute 
myeloid leukemia (IV) 
 
UPD has been detected in 20-30% of karyotypically normal AML (Gorletta et al. 2005, 
Raghavan et al. 2005) and in various cancers as a potential pathogenic mechanism 
(reviewed by Tuna et al. 2009). Tumor suppressors or oncogenes can be detected in 
regions of UPD that might be affected by either a mutation that can become 
homozygous with the UPD mechanism or epigenetic silencing. Homozygous mutations 
have been found in some of the genes suggested to be involved in AML pathogenesis 
such as FLT3, WT1, CEBPA, RUNX1, and CBL (Fitzgibbon et al. 2005, Griffiths et al. 
2005, Dunbar et al. 2008). Homozygous FLT3 mutations have also been suggested to 
have an adverse prognosis (Whitman et al. 2001). In Study IV, AML cases (n=19) were 
investigated using Affymetrix GeneChip Human Mapping 50K (XbaI) SNP-array for 
detection of cryptic copy number alterations and LOH.  
We detected LOH and potential UPD in several chromosomal regions. LOH was 
found in 12/19 cases (63%) (Table 8). Potential regions of UPD were detected in 10/19 
cases (53%). Recurrent LOH in our study was detected in 7q and 13q, suggesting that 
important genes in these chromosomes can be involved in karyotypically normal AML. 
In one case, the whole chromosome 13 showed UPD, which was confirmed by detecting 
the increased ITD-FLT3 mutant allele dosage from the agarose gel (lane 3, Figure 5). 
FLT3 is one of the known target genes of chromosome 13 in AML (Nakao et al. 1996, 
Yamamoto et al. 2001, Thiede et al. 2002). Two cases were detected with other 
potential regions of UPD than FLT3 region, suggesting also other possible target genes.  
The same AML cases were evaluated with aCGH using an Agilent 60K 
oligonucleotide array (Study II) and with SNP-array analysis using an Affymetrix 50k 
mapping array (Study IV). Thus, SNP-array results could be compared with aCGH data 
of the same cases. SNP-array analysis did not reveal additional copy number changes 
compared with Study II, but showed a 4.1-Mb amplification in 8q24.13-q24.21 and a 
3.6-Mb loss in 12p12.3. The smaller alterations (0.4-1.7) that were detected with aCGH 
were not visible with SNP-array. 8q24.13-q24.21 showed besides copy number 
alteration also LOH, suggesting preferential amplification of one allele. The differences 
between aCGH and SNP-array results could be explained by different spatial 
resolutions. Spatial resolution can in some cases be problematic in SNP-array analysis 
since the SNPs are not uniformly distributed throughout the genome (Coe et al. 2007). 
More densely arrayed SNP probes are required to achieve a resolution similar to that of 
oligonucleotide aCGH. There might also have been lower quality in SNP-array results 
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in our study compared with aCGH results since more steps, including PCR-based 
genome complexity reduction, are performed in the Affymetrix protocol.  
The aCGH experiment was faster to perform than the SNP-array experiment, 
and the protocol was less demanding, making aCGH a more convenient choice for 
diagnostic work. On the other hand, for research purposes, genome-wide SNP-array 
analysis might be the better option since more information is obtained in a single 
analysis. The availability of SNP-arrays with higher densities and the development of 
algorithms as well as usage of methodologies where genome complexity reduction is 
not needed can make SNP-array the most beneficial platform in the future. 
 
 
 
 
 
 
 
Figure 5. FLT3-ITD mutation test. Agarose gel illustrating the results of FLT3 mutation analysis. 
Lanes 1 and 10 show the DNA size standards. The arrows in the right side show the locations of mutant 
and wild-type bands. Lanes 2, 5, and 6 show patient samples with negative FLT3-ITD mutation status. 
Lane 3 shows a patient sample with ITD mutation and a more intense upper band reflecting the increased 
dosage of the mutant allele. Lane 4 shows a patient sample with an ITD mutation, but a more intense 
wild-type band. Lane 7 displays the PCR-negative control (H2O), lane 8 the positive control, and lane 9 
the wild-type control. 
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Table 8. Loss of heterozygosity regions detected with single nucleotide polymorphism microarray. 
Case no. Cytogenetic location bp location Size of alteration (MB)
4q31.1-q31.21 139996583-145144092 5,1
4q32.1-q34.1 157994837-175609159 17,6
16q13-q21 56562885-61294302 4,7
12p12.1-p11.22 24989341-30592175 5,6
13q 18300000-114142980 95,8
14q22.1-q22.3 50533072-55620173 5,1
3(4) normal
2q21.2-q22.1 134253668-138626175 4,4
7q21.11 81656156-85659633 4
7q21.12-q21.2 87329855-90967737 3,6
5(6) normal
6(7) 13q22.1-q31.1 73284990-79304088 6
7(8) normal
8(9) 18q12.1-q12.2 27637275-31998764 4,4
9(11) normal
3q12.1-q13.3 99474101-115623059 16,1
4q12-q13.1 55998070-64460188 8,5
4q21.1-q21.21 76653600-79616778 3
8p11.21-q11.23 40312067-54281947 14
12q14.1-q14.2 57581720-61962984 4,4
11(13) 2q14.2-q14.3 119648809-124972819 5,3
12(14) 17q12-q21.32 34176036-43615673 9,4
13(15) normal
1p21.2-p13.3 101650684-107327698 5,7
1q23.2-q23.3 156963203-161324123 4,4
7q21.11-q21.12 83598401-87661101 4,1
8q24.13-q24.22 126984731-131660463 4,7
15(17) normal
16(18) 13q21.1-q21.31 57989044-62966508 5
17(24) normal
1p32.2-p31.3 56290829-61321550 5
4q28.2-q28.3 129890398-135011057 5,1
1q22-q23.2 151606871-156963203 5,4
10p11.21-q11.22 35976759-49313232 13,3
19(26)
1(2)
2 (3)
4(5)
10(12)
14(16)
18(25)
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CONCLUSIONS 
 
Chromosomal alterations are considered important predictive and prognostic factors in 
leukemia, and many chromosomal imbalances are known; however, many target genes 
of these alterations remain obscure. Heterogeneity among molecular and clinical traits 
in AML and CLL has been described, especially in cases with normal karyotype. 
Genetic alterations are thought to explain some of this heterogeneity. 
Microarray methods aCGH and SNP-array are used to study chromosomal 
imbalances with high resolution enabling genome-wide molecular analysis of 
chromosomes without cell culturing. The detection of gene-level alterations and 
breakpoint detection in a single experiment without prior knowledge of the alterations 
are other benefits provided by the high resolution. New mutated genes are likely to be 
found in the regions with recurrent deletions, copy neutral LOH, or amplifications. 
Furthermore, the defining of minimal altered regions of the recurrent alterations can 
lead to identification of probable candidate genes involved in leukemia pathogenesis.  
The aim of this thesis was to detect novel chromosomal alterations and to 
characterize previously known alterations with high resolution among CLL and AML 
patients by using genomic microarray methods. In all studies, cryptic alterations were 
revealed with aCGH or SNP-array, and in Studies I and III known alterations were 
characterized at the gene level. 
In Study I, our aim was to characterize marker chromosomes with 11q 
amplicons by using aCGH in combination with other cytogenetic methods. A cryptic 
deletion causing the MLL-ARHGEF12 fusion gene in 11q was detected in AML. 
Amplified genes could be also identified in marker chromosomes composed of 
chromosomal material from 11q.  
Normal karyotype with standard G-banding is detected in 40-50% of AML cases 
and in 20% of CLL cases. One specific interest was to screen cryptic copy number 
alterations in karyotypically normal AML and CLL using aCGH. In addition, we 
analyzed LOH and UPD in karyotypically normal AML in Study IV. Array-CGH and 
SNP-array analyses were able to reveal novel aberrations that were undetectable with 
G-banding or cCGH. In karyotypically normal AML, we found cryptic copy number 
alterations with oligonucleotide aCGH in 15% of cases and regions of LOH, including 
potential UPD, with SNP-array in 63% of cases. In CLL, novel cryptic copy number 
alterations were detected in 15% of cases. 
We aimed also to define minimal common regions in case where recurrent 
alterations were detected. Searches for target oncogenes and tumor suppressors from 
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common cytogenetically altered regions have previously focused on mapping the 
minimal regions by FISH or LOH analyses. Array-CGH can reveal the minimal regions 
less laboriously than these methods. In this thesis, minimal regions with putative 
candidate genes could be defined in 13q14.3 and 11q22.3-q23.2 in CLL and in 11q24-
25 in AML. 
SNP-array and aCGH methods are effective screening methods that can reveal 
novel molecular alterations in cancer research. However, they can also be useful for 
some specific clinical diagnostic purposes. In diagnostics, the advantages of microarray 
methods would be in the potential discovery of small alterations in cases with cancer or 
constitutional disorders buth with normal karyotype, the identification of genes located 
in unknown marker chromosomes or in small deletions and amplifications, and the 
detection of small deletions and amplifications associated with apparently balanced 
chromosomal translocations. Microarray methods also enable analysis of genome-wide 
gene copy number alterations in tumors that are difficult to grow in cell cultures. In 
leukemia diagnosis, the discovery of potential MRD markers with microarray methods 
can be advantageous. When analyzing the MRD in leukemia patients after treatment, 
MRD markers are needed. The patients with a normal karyotype in diagnosis and no 
other potential MRD markers such as a specific mutation, can benefit from aCGH 
analysis of the diagnostic sample because aCGH might reveal a submicroscopic copy 
number alteration that can later be used as a MRD marker and be analyzed with more 
sensitive method such as FISH or RT-PCR. Array-CGH findings can be informative 
also in cases where a cryptic alteration with prognostic significance is detected, possibly 
changing the prognostic group to which the patient is classified. Furthermore, detected 
cryptic alterations provide candidate oncogenes and tumor suppressors for future 
studies. 
Some limitations also exist in current aCGH analyses. The high-resolution 
analyses might in some cases have problems distinguishing cancer-associated changes 
from copy number variation. Some copy number polymorphisms were overlapping, 
with some of the smallest cryptic alterations detected in Studies II and III. However, the 
detected alterations were mostly larger in size than the polymorphisms. Another 
limitation is that one clone produced from one progenitor cell with many alterations 
cannot be distinguished from several different clones originating from different 
progenitors. In addition, the proportion of aberrant cells needed in samples has been 
suggested to range between 20% and 30% for reliable detection with aCGH (Ballif et al. 
2006, Gondek et al. 2008). For example, in three CLL cases in Study III, alterations 
detected in only two cells with G-banding were not visible with aCGH. Since balanced 
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ploidies, translocations, or inversions are not visible in genomic microarray analyses, 
standard cytogenetic techniques are still needed in diagnostic laboratories.  
Array-CGH and SNP-array analyses are nevertheless useful methods for 
obtaining the ”molecular karyotype”. These methods allow the chromosomal alterations 
to be viewed at the gene-level resolution in a single experiment, providing a fast and 
precise analysis. The studies of this thesis together with previous literature indicate that 
aCGH can be a valuable addition to the existing technology. Conventional methods, 
such as G-banding karyotyping and FISH, are still needed for comprehensive 
diagnostics of leukemia samples, but the new array technologies have proved their 
power in high-resolution, genome-wide, and cost-effective analyses. 
Besides current microarray techniques, future cancer research and diagnostics 
will likely be strongly affected by next-generation sequencing (NGS) techniques 
(reviewed by Ansorge 2009). With these techniques, a large number of sequences can 
be produced considerably faster and more cost-effectively than with traditional 
sequencing. Either whole genome or targeted regions can be analyzed. In cancer 
research, these techniques have already started to be utilized. For example, novel 
mutated genes were found in karyotypically normal AML patient with whole genome 
NGS (Ley et al. 2008). Besides mutation analysis, NGS has various potential 
applications, including genome-wide analysis of epigenetic alterations, transcription 
factor regions, or gene expression (reviewed by Ansorge 2009). Thus, NGS techniques 
may someday replace some of the current microarray applications. At present, these 
techniques are limited by their high costs, time-consuming data analysis, and data 
storage requirements, as well as by some technical challenges. However, they are 
among the most promising future genome analysis technologies. 
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